Motor, Non-motor and Genetic Determinants of Progression in Parkinson's Disease: A Mexican Multicenter Cohort Study

Motor, Non-motor and Genetic Determinants of Progression and Complications in Parkinson's Disease: A Multicenter Cohort Study in Mexican Population (ReMePArk)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01865877

Acronym

ReMePARK

Enrollment

550

Registered

2013-05-31

Start date

2012-08-31

Completion date

2016-08-31

Last updated

2017-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Parkinson's disease, Motor, Non-motor, Progression, Complications

Brief summary

The objective of the study is to assess the effect of motor, non-motor and genetic factors on the progression of Parkinson's disease as well as its impact on complications rates. A large sample of Mexican subjects with Parkinson's disease attending several referral centers will be included. Data collected will include disease severity and motor scales, non-motor scales as well as genotyping for monogenic forms of the disease. Assessments will be performed every 6 months for two years.

Detailed description

Demographic and clinical data will be collected after obtaining a signed informed consent. Recruitment will be competitive. Data collected includes age, gender, motor phenotype, age at onset, age at diagnosis, smoking history, family history, antiparkinsonic treatment, other treatments and a complete neurological evaluation.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 95 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of Parkinson's disease by the United Kingdom Parkinson's disease Society Brain Bank Criteria * Any gender * Any Hoehn and Yahr stage * Written informed consent

Exclusion criteria

* Severe comorbidity that may limit proper neurological evaluation as judged by the investigator * Subjects with atypical or secondary parkinsonism

Design outcomes

Primary

Measure	Time frame	Description
To assess motor scale change over time	Every 6 months for 2 years	Motor symptoms will be assessed by proper and validated motor scales; also minimal clinically important change will be determined.

Secondary

Measure	Time frame	Description
To assess non-motor symptoms over time	Every 6 months for 2 years	Non-motor symptoms will be assessed using proper validated scales. Frequency and severity will be recorded.
To assess quality of life change over time.	Every 6 months for 2 years	Health-related quality of life will be assessed with proper validated clinimetric instruments.
To assess caregiver burden as disease progresses	Every 12 months for 2 years	Caregiver burden will be assessed by proper validated scales.

Other

Measure	Time frame	Description
To assess the change in prevalence of neuropsychiatric symptoms over time	Every 12 months for 2 years	Prevalence and incidence of depression, apathy, cognitive decline, psychosis and impulse control disorder will be determined.

Countries

Mexico

Outcome results